Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device

Teruhiko Imamura; Koichiro Kinugawa; Masaru Hatano; Naoko Kato; Shun Minatsuki; Hironori Muraoka; Toshiro Inaba; Hisataka Maki; Taro Shiga; Atsushi Yao; Shunei Kyo; Minoru Ono; Ryozo Nagai

doi:10.1007/s10047-012-0662-4

Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device

Teruhiko Imamura^*, Koichiro Kinugawa, Masaru Hatano, Naoko Kato, Shun Minatsuki, Hironori Muraoka, Toshiro Inaba, Hisataka Maki, Taro Shiga, Atsushi Yao, Shunei Kyo, Minoru Ono, Ryozo Nagai

^*この論文の責任著者

内科学（第二）講座

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

14 被引用数 (Scopus)

抄録

No medical treatment has been established to ameliorate pulmonary hypertension (PH) due to left heart disease. Heart transplantation (HTx) is thus far the definitive therapy for stage D heart failure, but concomitant PH is one of the major risk factors for death after HTx. Recently, implantation of a left ventricular assist device (LVAD) has been reported to improve PH and has become a major bridge tool for HTx. We experienced a rare case with persistent PH even after the implantation of a continuous-flow LVAD. The administration of an endothelin receptor antagonist, bosentan, significantly decreased pulmonary vascular resistance. Combination therapy with LVAD implantation and anti-PH medication may be useful for patients with stage D heart failure complicated with severe PH.

本文言語	英語
ページ（範囲）	101-104
ページ数	4
ジャーナル	Journal of Artificial Organs
巻	16
号	1
DOI	https://doi.org/10.1007/s10047-012-0662-4
出版ステータス	出版済み - 2013/03

ASJC Scopus 主題領域

医学（その他）
生体材料
生体医工学
循環器および心血管医学

文献へのアクセス

10.1007/s10047-012-0662-4

引用スタイル

@article{c584844c2d7c4e4ca2608719879c3887,

title = "Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device",

abstract = "No medical treatment has been established to ameliorate pulmonary hypertension (PH) due to left heart disease. Heart transplantation (HTx) is thus far the definitive therapy for stage D heart failure, but concomitant PH is one of the major risk factors for death after HTx. Recently, implantation of a left ventricular assist device (LVAD) has been reported to improve PH and has become a major bridge tool for HTx. We experienced a rare case with persistent PH even after the implantation of a continuous-flow LVAD. The administration of an endothelin receptor antagonist, bosentan, significantly decreased pulmonary vascular resistance. Combination therapy with LVAD implantation and anti-PH medication may be useful for patients with stage D heart failure complicated with severe PH.",

keywords = "Endothelin receptor antagonist, Out of proportion, Postcapillary",

author = "Teruhiko Imamura and Koichiro Kinugawa and Masaru Hatano and Naoko Kato and Shun Minatsuki and Hironori Muraoka and Toshiro Inaba and Hisataka Maki and Taro Shiga and Atsushi Yao and Shunei Kyo and Minoru Ono and Ryozo Nagai",

year = "2013",

month = mar,

doi = "10.1007/s10047-012-0662-4",

language = "英語",

volume = "16",

pages = "101--104",

journal = "Journal of Artificial Organs",

issn = "1434-7229",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device

AU - Imamura, Teruhiko

AU - Kinugawa, Koichiro

AU - Hatano, Masaru

AU - Kato, Naoko

AU - Minatsuki, Shun

AU - Muraoka, Hironori

AU - Inaba, Toshiro

AU - Maki, Hisataka

AU - Shiga, Taro

AU - Yao, Atsushi

AU - Kyo, Shunei

AU - Ono, Minoru

AU - Nagai, Ryozo

PY - 2013/3

Y1 - 2013/3

N2 - No medical treatment has been established to ameliorate pulmonary hypertension (PH) due to left heart disease. Heart transplantation (HTx) is thus far the definitive therapy for stage D heart failure, but concomitant PH is one of the major risk factors for death after HTx. Recently, implantation of a left ventricular assist device (LVAD) has been reported to improve PH and has become a major bridge tool for HTx. We experienced a rare case with persistent PH even after the implantation of a continuous-flow LVAD. The administration of an endothelin receptor antagonist, bosentan, significantly decreased pulmonary vascular resistance. Combination therapy with LVAD implantation and anti-PH medication may be useful for patients with stage D heart failure complicated with severe PH.

AB - No medical treatment has been established to ameliorate pulmonary hypertension (PH) due to left heart disease. Heart transplantation (HTx) is thus far the definitive therapy for stage D heart failure, but concomitant PH is one of the major risk factors for death after HTx. Recently, implantation of a left ventricular assist device (LVAD) has been reported to improve PH and has become a major bridge tool for HTx. We experienced a rare case with persistent PH even after the implantation of a continuous-flow LVAD. The administration of an endothelin receptor antagonist, bosentan, significantly decreased pulmonary vascular resistance. Combination therapy with LVAD implantation and anti-PH medication may be useful for patients with stage D heart failure complicated with severe PH.

KW - Endothelin receptor antagonist

KW - Out of proportion

KW - Postcapillary

UR - http://www.scopus.com/inward/record.url?scp=84875229220&partnerID=8YFLogxK

U2 - 10.1007/s10047-012-0662-4

DO - 10.1007/s10047-012-0662-4

M3 - 学術論文

C2 - 23015200

AN - SCOPUS:84875229220

SN - 1434-7229

VL - 16

SP - 101

EP - 104

JO - Journal of Artificial Organs

JF - Journal of Artificial Organs

IS - 1

ER -

Bosentan improved persistent pulmonary hypertension in a case after implantation of a left ventricular assist device

抄録

ASJC Scopus 主題領域

文献へのアクセス

フィンガープリント

引用スタイル